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Background: Small studies suggest an association of donor-specific anti-human leukocyte antigen (HLA) antibodies
(DSAs) with primary graft failure (GF) following haploidentical stem cell transplantation, but primary graft rejection (GR)
was not discriminated from primary poor graft function (PGF). In this study, we aimed to determine the association of
DSAs with primary GF, including GR and PGF, in patients who underwent unmanipulated haploidentical blood and
marrow transplantation.
Methods: A total of 345 subjects were prospectively recruited and randomly selected as training group (n = 173) and
validation group (n = 172). Patient plasma/serum was screened. For HLA antibody positive samples with a median
fluorescent intensity (MFI) >500, DSAs were further tested using a LABScreen Single Antigen Kit (One Lambda).
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Results: A total of 342 patients (99.1 %) achieved sustained myeloid engraftment. The median times to neutrophil
engraftment and platelet engraftment were 13 days (range, 8–28 days) and 18 days (range, 6–330 days), respectively.
The cumulative incidence of primary GF was 6.4 ± 1.3 % and included GR (0.9 ± 0.5 %) and PGF (5.5 ± 1.2 %). Of the 345
cases tested, 39 (11.3 %) were DSA positive. Multivariate models showed that DSAs (MFI≥ 10,000) were correlated to
primary GR (P < 0.001) and that DSAs (MFI≥ 2000) were strongly associated with primary PGF (P = 0.005). All patients
were classified into three groups for analysis. Group A included cases that were DSA negative and those with a DSA
MFI <2000 (n = 316), group B included cases with a 2000≤MFI < 10,000 (n = 19), and group C included cases with a
MFI ≥10,000 (n = 10). The DSAs were associated with an increased incidence of the primary GF (3.2 vs. 31.6 vs. 60 %, for
groups A, B, and C, respectively, P < 0.001), transplant-related mortality (TRM) rate (17.2 vs. 14.7 vs. 33.3 %, for groups A,
B, and C, respectively, P = 0.022), and inferior overall survival (OS, 77.3 vs. 85.3 vs. 44.4 %, for groups A, B, and C,
respectively, P = 0.015). The primary GF was independently associated with a higher incidence of TRM (P < 0.001), inferior
disease-free survival (P < 0.001), and OS (P < 0.001).
Conclusions: The findings confirmed the effect of DSAs on primary GF, including GR and PGF, and survival. Our results
suggest incorporating DSAs in the algorithm for haploidentical donor selection.Background
Allogeneic stem cell transplantation (allo-SCT) is a po-
tentially curative treatment for patients with hematologic
malignancies [1–7]. However, complications, such as graft
failure (GF) and relapse, remain serious problems [4, 5,
8–16]. Primary GF includes graft rejection (GR), which
is defined as a failure to engraft neutrophils (absolute
neutrophil count (ANC) ≤0.5 × 109/L) by day +28 for
three consecutive days and the absence of donor
hematopoiesis [14, 17]. It also includes poor graft function
(PGF), which is the failure to achieve two or three adequate
blood counts (ANC ≤0.5 × 109/L, platelet ≤20 × 109/L, or
hemoglobin (Hb) ≤80 g/L) following allo-SCT in the pres-
ence of complete donor hematopoiesis [12, 14, 17]. The in-
cidence of primary GF ranges from 2 to 15 % in patients
who undergo human leukocyte antigen (HLA)-matched
sibling donor transplantation, unrelated donor trans-
plantation (MUDT), or umbilical cord blood transplant-
ation (UCBT) [10, 13, 18–22]. In the past 10 years,
HLA-mismatched/haploidentical transplants (haplo-SCTs)
have been used more frequently [1–5, 23–25]; as a result,
GF has become an increasing problem that contributes to
high morbidity and mortality after transplantation. The in-
cidences of GF in patients who underwent CD34-selected
[5] and CD3/CD19-depleted haplo-SCTs [4] were 9 and
8 %, respectively. The rate of GF following haplo-SCTs
with post-transplant cyclophosphamide was 13 % [8, 25].
Donor-specific antibodies (DSAs) refer to anti-HLA anti-
bodies that specifically correspond to a mismatched anti-
gen of the donor [9, 20–22, 26–28]. The role of DSAs in
solid organ transplantation is well established [29]. In allo-
SCTs [20, 21, 30], DSAs have been associated with primary
GF after either MUDT or UCBT. In haplo-SCT, Ciurea
et al. [22] showed that 75 % of pretransplant DSA-positive
patients with a median fluorescent intensity (MFI) >1500
failed to engraft, compared with 5 % of DSA-negativepatients (P = 0.008). In another study, the authors found
that three of five patients with high levels of DSA (MFI >
10,000) had GF. [9] Although the association of DSAs
with primary GF after haplo-SCT has been observed
[9, 22, 31], there are some limitations of previous studies:
(1) most studies were retrospective [22, 31], except one
[9]; (2) they included small numbers of patients [9, 22, 31];
(3) primary GR was not discriminated from primary PGF
[9, 22, 31]; and (4) there were no training and validation
groups [9, 22, 31].
In our center, we established an unmanipulated haploi-
dentical blood and marrow transplant (HBMT) protocol
that can achieve outcomes comparable with HLA-identical
sibling or unrelated donor transplantation. The incidence
of primary GR was approximately 1 % in patients undergo-
ing unmanipulated HBMT. [1, 32] However, we found that
primary PGF, with an incidence of approximately 4–5 %,
was a severe complication with a higher incidence of
mortality after unmanipulated HBMT (unpublished data).
Therefore, we prospectively investigated the influence of
DSAs on primary GF, including GR and PGF, after unma-
nipulated HBMT in a training group of 173 patients
and validated the results in an independent cohort of
172 cases.Results
Patient characteristics
The median age of the patients was 26 years (range, 2–
58 years). All patients were treated with a myeloablative
conditioning regimen. The median infused total nucleated
cell dose (TNC) and CD34+ cell dose were 8.34 × 108/kg
(range, 1.78–23.69 × 108/kg) and 2.59 × 106/kg (range,
0.39–16.82 × 106/kg), respectively. Other demographics
are listed in Table 1. The characteristics of the patients
in the training group and validation set were similar.
Table 1 Patient and donor characteristics
All patients Training group Validation group P value
Patient number 345 173 172
Median age (range), years 26 (2–58) 26 (4–58) 26 (2–58) 0.830
Median weight (range), kg 62 (13–113) 61 (18–113) 63 (13–110) 0.388
Male sex, n (%) 201 (58.3) 100 (57.8) 101 (58.7) 0.863
Diagnosis, n (%) 0.142
AML 137 (39.7) 69 (39.9) 68 (39.5)
ALL 116 (33.6) 49 (28.3) 67 (39.0)
CML 19 (5.5) 10 (5.8) 9 (5.2)
MDS 38 (11.0) 24 (13.9) 14 (8.1)
Others 35 (10.1) 21 (12.1) 14 (8.1)
Disease status, SR/HR (n (%)) 265 (76.8)/80 (23.2) 135 (78.0)/38 (22.0) 135 (78.0)/38 (22.0) 0.589
Conditioning regimen
MA 345 (100 %) 173 (100 %) 172 (100 %)
No of HLA-A, B, DR mismatched 0.302
0 2 (0.6 %) 1 (0.6 %) 1 (0.6 %)
1 18 (5.2 %) 13 (7.5 %) 5 (2.9 %)
2 74 (21.4 %) 34 (19.7) 40 (23.3 %)
3 249 (72.2 %) 124 (71.1 %) 125 (72.2 %)
Donor-recipient sex match, n (%) 0.609
Male-male 132 (38.3) 63 (36.4) 69 (40.1)
Male-female 89 (25.8) 42 (24.3) 47 (27.3)
Female-male 71 (20.6) 38 (22.0) 33 (19.2)
Female-female 53 (15.4) 30 (17.3) 23 (13.4)
Donor-recipient relationship, n (%) 0.419
Father-child 134 (38.8) 64 (37.0) 70 (40.7)
Mother-child 45 (13.0) 28 (16.2) 17 (9.9)
Sibling-sibling 103 (29.9) 53 (30.6) 50 (29.1)
Child-parent 53 (15.4) 25 (14.5) 28 (16.3)
Other 10 (2.9) 3 (1.7) 7 (4.1)
ABO matched, n (%) 0.345
Matched 196 (56.8) 102 (59.2) 94 (54.7)
Major mismatched 64 (18.6) 34 (19.7) 30 (17.4)
Minor mismatched 18 (5.2) 10 (5.8) 8 (4.7)
Bidirect mismatched 67 (19.4) 27 (15.6) 40 (23.3)
Cell compositions in allografts
Infused nuclear cells 108/kg 8.34 (1.78–23.69) 8.32 (1.78–23.59) 8.40 (2.12–23.69) 0.321
Infused CD34+ cells 106/kg 2.59 (0.39–16.82) 2.71 (0.39–14.47) 2.49 (0.58–16.82) 0.840
Infused lymphocytes 108/kg 2.95 (0.16–9.49) 2.88 (0.16–9.49) 3.06 (0.68–7.34) 0.107
Infused CD3+ cells 108/kg 2.00 (0.10–5.93) 2.00 (0.10–5.93) 1.99 (0.20–5.36) 0.575
Infused CD4+ cells 108/kg 1.10 (0.10–3.94) 1.09 (0.10–3.33) 1.13 (0.19–3.94) 0.371
Infused CD8+ cells 108/kg 0.70 (0.05–2.47) 0.69 (0.05–2.47) 0.72 (0.14–2.43) 0.452
Infused CD14+ cells 108/kg 1.49 (0.05–4.90) 1.50 (0.33–4.90) 1.48 (0.05–6.13) 0.769
Abbreviations: AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, HLA human
leukocyte antigen, BM bone marrow
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A total of 342 patients (99.1 %) achieved sustained mye-
loid engraftment. The median times to neutrophil en-
graftment and platelet engraftment were 13 days (range,
8–28 days) and 18 days (range, 6–330 days), respectively.
The cumulative incidence of primary GF was 6.4 ± 1.3 %
and included GR (n = 3, 0.9 ± 0.5 %) and PGF (n = 19,
5.5 ± 1.2 %). At 100 days after transplant, the cumulative
incidence of grade 2 to 4 acute graft-versus-host disease
(GVHD) was 42.7 ± 3.1 %. After a median follow-up of
384 days (range, 25–784 days), the cumulative incidence
of chronic GVHD was 43.3 ± 3.1 %. The 2-year prob-
abilities of relapse, transplant-related mortality (TRM),
disease-free survival (DFS), and overall survival (OS) were
8.8 ± 1.8 %, 18.4 ± 2.8 %, 75.1 ± 2.9 %, and 76.2 ± 3.0 %,
respectively.Anti-HLA antibodies and DSAs
Of the 345 cases tested, 87 (25.2 %) were anti-HLA anti-
body positive, including 44 males and 43 females. Of the
positive cases, 39 (11.3 %) were DSA positive. Among
the 39 cases, 31 had antibodies against HLA class I anti-
gens, 15 had antibodies against HLA class II, and 7 against
classes I and II. The MFI was 4726 (range, 504–19,948).
Among 144 female cases, the patients with a pregnancy
history had a higher anti-HLA antibody positive rate (100
vs. 17.2 %, P < 0.001) and a higher DSA positive rate (59.1
vs. 8.2 %, P < 0.001) than those without.Association of DSAs on primary GR after transplantation
In this study, we defined a MFI ≥ 10,000 of DSAs as a
cutoff value for primary GR using receiver operating
characteristic curves in all the 345 patients who under-
went unmanipulated HBMT due to the low incidence of
primary GR [1, 2, 32]. The incidence of primary GR with
a MFI ≥10,000 was higher than those with a MFI <10,000
(20 vs. 0.3 %, P = 0.002) in all the 345 patients. The num-
bers of patients with primary GR in training and validation
sets were two cases and one case, respectively. The higher
incidences of primary GR in patients with a MFI ≥ 10,000
than those with a MFI < 10,000 were also observed in the
training group (16.7 vs. 0.6 %, P = 0.041) and the validation
group (25.0 vs. 0 %, P = 0.023). Univariate analysis showed
that factors, including age (P = 0.002), disease status (P =
0.018), donor-recipient relationship (P = 0.057), anti-HLA
antibodies (P < 0.001), and DSAs (P < 0.001), were cor-
related with primary GR after unmanipulated HBMT.
Multivariate analysis demonstrated that the presence of
DSAs (MFI ≥ 10,000) was associated with primary GR
(hazard ratio (HR) 71.556, 95 % confidence interval (CI)
6.488–789.129; P < 0.001). The onset of primary GR was
associated with increased TRM (HR 18.893, 95 % CI
5.538–64.452; P < 0.001), inferior DFS (HR 9.883, 95 % CI3.005–32.502; P < 0.001), and OS (HR 11.747, 95 % CI
3.546–38.916; P < 0.001).
Association of DSAs with primary PGF after
unmanipulated HBMT
We further investigated the effects of DSAs on primary
PGF after unmanipulated HBMT. In the training set
(n = 173), a cutoff value of a DSA MFI ≥2000 was iden-
tified to predict the onset of primary PGF. The patients
with a MFI ≥2000 experienced a significantly higher inci-
dence of primary PGF than those with a MFI <2000
[27.3 % (3/11) vs. 1.9 % (3/162), P = 0.003]. Multivariate
models showed that the presence of DSAs was strongly
associated with primary PGF (HR 10.575, 95 % CI 2.029–
55.117; P = 0.005). The same threshold of DSAs was ap-
plied in the independent validation set of the 172 patients.
In the validation group, the incidence of primary PGF was
higher in patient with a MFI ≥2000 compared with those
with a MFI <2000 [33.3 % (6/18) vs. 4.5 % (7/154), P =
0.001]. Multivariate analysis further confirmed the pres-
ence of DSAs was independently associated with the onset
of primary PGF (HR 3.949, 95 % CI 1.501–10.389; P =
0.005) after unmanipulated HBMT. After identifying pri-
mary GR as a competing risk for primary PGF, the correl-
ation of DSAs with primary PGF was also demonstrated
in the training group and the validation group (data not
shown).
In the training set, multivariate analysis showed that
the onset of primary PGF was independently associated
with a higher incidence of TRM (HR 7.114, 95 % CI
2.054–24.639; P = 0.002), inferior DFS (HR 3.356, 95 %
CI 1.047–10.759; P = 0.042), and OS (HR 3.687, 95 % CI
1.129–12.039; P = 0.031). These independent associations
of primary PGF with a higher incidence of TRM (HR
5.031, 95 % CI 1.993–12.704; P = 0.001), inferior DFS (HR
3.011, 95 % CI: 1.247–7.617; P = 0.014), and OS (HR 3.530,
95 % CI 1.445–8.626; P = 0.006) were confirmed in the val-
idation group.
Effects of DSA on primary graft failure and transplant
outcomes
After separately analyzing the association of DSAs with
either primary GR or primary PGF, we further investi-
gated the association of DSAs with primary GF, including
both GR and PGF, in all the 345 patients. These patients
were classified into three groups, group A included cases
that were DSA negative or had a DSA MFI <2000 (n =
316), group B included cases with a 2000 ≤MFI < 10,000
(n = 19), and group C included those with a MFI ≥10,000
(n = 10). The cumulative incidence of neutrophil engraft-
ment of patients in group A was 100 %, which was sig-
nificantly higher than the cumulative incidence of group C
(80.0 ± 12.6 %, P = 0.005) and comparable with group B
(94.7 ± 5.1 %, P = 0.169) (Fig. 1a). The cumulative incidence
Fig. 1 Pretransplant DSA and cumulative incidence of neutrophil (a)
and platelet (b) engraftment. All patients were classified into three
groups, group A includes cases with DSA negative and those with a
DSA MFI <2000 (n = 316, solid line), group B includes cases with
2000 ≤MFI < 10,000 (n = 19, dotted line), and group C includes those
with a MFI ≥ 10,000 (n = 10, dashed line)
Table 2 Multivariate analysis of factors associated with transplant
outcomes
HR 95 % CI P value
Primary graft failure
DSA
MFI ≥ 10,000 1
2000 ≤MFI < 10,000 0.940 0.284–3.177 0.919
MFI < 2000 0.187 0.048–0.730 0.016
OS
Disease status 2.839 1.702–4.736 0.000
Primary graft failure
GR 1
PGF 0.271 0.074–1.000 0.050
No primary graft failure 0.068 0.020–0.229 0.000
DFS
Disease status 3.593 2.212–5.836 0.000
PGF 3.125 1.564–6.244 0.000
GR 1
PGF 0.284 0.077–1.044 0.058
No primary graft failure 0.084 0.025–0.279 0.000
Relapse




PGF 0.209 0.056–0.790 0.021
No primary graft failure 0.031 0.0009–0.107 0.000
ANC
CD34 1.370 1.106–1.697 0.004
PLT
CD34 1.483 1.187–1.852 0.001
DSA
MFI≥ 10,000 1
2000≤MFI < 10,000 3.074 1.137–8.311 0.027
MFI < 2000 3.301 1.358–8.022 0.008
Abbreviations: HR hazard ratio, CI confidence interval, DSAs donor-specific
antibodies, MFI median fluorescence intensity, OS overall survival, GR graft
rejection, PGF poor graft function, DFS disease-free survival, TRM transplant-
related mortality, ANC absolute neutrophil count, PLT platelet
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1.30 %, which was significantly higher than the incidences
of group B (93.9 ± 5.9 %, P = 0.030) and group C (77.5 ±
18.1 %, P = 0.004) (Fig. 1b). Multivariate analysis showed
that the presence of DSAs was strongly associated with
platelet engraftment and primary graft failure, but not
neutrophil engraftment (Table 2).
The incidences of primary GF, including GR and PGF,
in groups A, B, and C were 3.2 % (10/316), 31.6 % (6/19),
and 60 % (6/10), respectively (P < 0.001). The cumulative
incidences of the TRM rate were 17.2 %, 14.7 %, and
33.3 %, for patients in groups A, B, and C, respectively
(Fig. 2a, P = 0.022). The overall survival rates were 77.3,
85.3, and 44.4 % for patients in groups A, B, and C, re-
spectively (Fig. 2b, P = 0.015). Multivariate analysis showed
that the presence of DSAs was strongly associated with
primary GF (Table 2). The onset of primary GF was also
independently associated with a higher incidence of TRM
and inferior DFS and OS (Table 2 and Fig. 3a, b). As
shown in Table 3, the causes of death in patients withprimary GF were mainly infections and hemorrhage, which
occurred significantly more often than those without GF
(P < 0.001). There were no effects of DSAs on GVHD and
relapse (Table 2).
Discussion
We confirmed the association of DSAs with primary GF,
as previously reported [9, 22], in this prospective study
with randomly assigned training and validation sets. This
Fig. 2 Transplant-related mortality (a) and overall survival (b). All patients
were classified into three groups, group A includes cases with DSA
negative and those with a DSA MFI <2000 (n = 316, solid line), group B
includes cases with 2000 ≤MFI < 10,000 (n = 19, dotted line), and group
C includes those with a MFI ≥10,000 (n = 10, dashed line)
Fig. 3 Transplant-related mortality (a) and overall survival (b). The solid
line, dotted line, and dashed line represents patients without primary graft
failure, with graft rejection, and with poor graft function, respectively
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15, 16, 20–22, 28, 30] suggests that the presence of
DSAs may contribute to the pathophysiology of GF not
only in MUDT and UCBT but also in haplo-SCT with T
cell depletion or T cell replete. Most importantly, for the
first time, we found a correlation between the presence
of DSAs and primary PGF, indicating that DSAs may be
involved in the pathogenesis of this complication. The
finding that primary GF, including both GR and PGF,
can result in inferior OS provides evidence that the pres-
ence of DSAs must be considered when choosing a hap-
loidentical donor and should be incorporated in the
donor selection algorithm [2, 33].
Our previous reports of a low incidence of primary
GR [32, 34] and the association of DSAs with primary
GR led us to this investigation of the effects of DSAs on
primary PGF in patients receiving our haploidentical
transplant protocol. [1, 2, 32, 34] Importantly, we identi-
fied for the first time that a MFI ≥2000 was the DSA
threshold for primary PGF after haplo-SCT. Our results
demonstrated that the presence of DSAs was stronglyassociated with the onset of primary PGF, in both the train-
ing and validation sets. Moreover, we found that primary
PGF was an independent variable, which led to inferior
survival. Therefore, except for CD34(+)-selected stem cell
boost and other methods [13, 17], targeting DSAs may
provide a novel method to treat PGF, although the DSA
MFI threshold for primary PGF needs to be confirmed
in other haploidentical transplant modalities.
The definition of a threshold for DSAs, according to
MFI, is a premise for analyzing the association of DSAs
with primary GF. In CBTs, Takanashi et al. [30] considered
a MFI >1000 to be DSA positive. In a case-control study
conducted by Ciurea et al. [20], a MFI ≥500 was consid-
ered positive. In haplo-SCT, MFI values >1500 or 5000
were defined as DSA positive by Ciurea et al. [22] and
Yoshihara et al. [9], respectively. In our study, we identify
a MFI ≥10,000 and MFI ≥2000 as the cutoff values for pri-
mary GR and primary PGF, respectively. The differences
in the reported thresholds of DSAs between other studies
[9, 20–22] and this report may be related to different
transplant protocols and different methods for DSA de-
tection [9, 10, 15, 16, 20–22, 28, 30], although these studies
demonstrated that the antibody titer is important for the
Table 3 Causes of death for patients who underwent unmanipulated HBMT
Causes of deatha All patients (n = 345) Patients with primary GF (n = 22) Patients without primary GF (n = 323)
Relapse 18 (5.2 %) 1 (4.5 %) 17 (5.3 %)
Infections 27 (7.8 %) 8 (36.4 %) 19 (5.9 %)
Hemorrhage 7 (2.0 %) 3 (13.6 %) 4 (1.2 %)
GVHD 3 (0.9 %) 0 (0 %) 3 (0.9 %)
Others 8 (2.4 %) 1 (4.5 %) 7 (2.1 %)
Abbreviations: HBMT haploidentical blood and marrow transplantation, GF graft failure, GVHD graft-versus-host disease
aIndicate the number (%) of patients
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that high and low antibody titers of DSAs led to GR and
PGF, respectively. Both GR and PGF contributed to inferior
survival, although the survival was reduced in GR com-
pared with PGF (Fig. 3). Therefore, our results suggest
that high and low MFIs of DSAs should be dealt with
differently.
After investigating the association of DSAs with GR
and PGF, respectively, we further investigated this asso-
ciation of DSAs with primary GF by classifying all the
345 patients into three groups according to the cutoff
value of the DSA MFI. We found that patients with a
DSA MFI ≥10,000 experienced a significantly lower cumu-
lative incidence of platelet engraftment, but not neutrophil
engraftment, after multivariate analysis. This finding is in
agreement with a previous study [9]. The result of the lack
of an effect of DSAs on neutrophil engraftment may be re-
lated to the routine use of G-CSF in our transplant proto-
col. [1, 32] Moreover, the effect of DSAs on primary PGF
was also demonstrated in the overall cohort. As demon-
strated by Cutler et al. [21] in CBTs, we showed that pre-
transplant DSAs were associated with a higher TRM rate
and inferior survival, although a multicenter study with a
larger sample of cases is needed to confirm these effects in
multivariate analysis. Our study results support the logical
theory that the presence of DSAs results in primary GF
and may contribute to inferior survival.
Previous studies demonstrated that DSAs may kill donor
cells through antibody-dependent cell-mediated cytotox-
icity (ADCC) [26], indicating that an immune-mediated
mechanism may contribute to the pathogenesis of primary
GF. In the present study, the findings that a high MFI of
DSAs led to GR and a low MFI resulted in PGF suggest
that not only the onset GR but also PGF may involve
immune-mediated mechanisms. In renal transplantation,
DSAs may result in allograft injury though endothelial cell
apoptosis [35, 36]. In systemic sclerosis, the ADCC effect
via the Fas pathway can lead to bone marrow (BM) endo-
thelial cell apoptosis [37]. Based on previous reports
[35, 36] and the results of this study, it is conceivable that
higher titers of DSAs directed against antigens expressed
by all full donor cells may lead to necrosis, resulting in
primary GR. While, lower titers of DSAs directed againstantigens of donor cells may cause apoptosis and the onset
of primary PGF. [14, 15] Our study suggests that ab-
normalities in the BM microenvironment, especially
endothelial progenitor cells (EPCs), may cause PGF. [14]
Therefore, the effects of DSAs on the BM microenviron-
ment, especially EPCs, during the development of primary
GF should be further investigated.
Conclusions
The findings of this study confirmed the effects of DSAs
on primary GR. Impressively, we, for the first time, dem-
onstrated that the presence of DSAs might contribute to
the pathogenesis of primary PGF after unmanipulated
HBMT. Due to the involvement of DSAs in primary GF,
including GR and PGF, and inferior survival, the propor-
tions of DSAs can be used in haploidentical transplant
settings to decide who is the best donor [2, 33].
Methods
Study cohort
Patients who underwent unmanipulated HBMT were eli-
gible for this study and prospectively enrolled. All cases
were treated according to our institutional transplant
protocol, as previously described in detail [1, 32, 34]. A
total of 345 subjects were recruited between May 2012
and March 2014. These cases were randomly selected as
part of the training group (n = 173) or validation group
(n = 172). The protocol was approved by the Institutional
Review Board of Peking University and signed informed
consent was obtained from all the subjects. This study was
conducted in accordance with the Declaration of Helsinki.
Transplant protocol
Institutional protocols for unmanipulated HBMT have
been previously described [32, 34]. In brief, the condition-
ing therapy was consisted of cytarabine (4 g/m2/day, on
days −10 to −9), busulfan (3.2 mg/kg/day, intravenously
on days −8 to −6), cyclophosphamide (1.8 g/m2/day, on
days −5 to −4), 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-
1-nitrosourea (Me-CCNU, 250 mg/m2, once on day −3),
and ATG (2.5 mg/kg/ day, rabbit; Sang Stat, Lyon, France,
on days −5 to −2) [38]. All transplant recipients received
mixture allografts of G-CSF-mobilized bone marrow and
Chang et al. Journal of Hematology & Oncology  (2015) 8:84 Page 8 of 10peripheral blood stem cell harvests. Cyclosporine A,
mycophenolate mofetil, and short-term methotrexate were
used for prophylaxis of GVHD [39]. Cytomegalovirus
(CMV) and Epstein-Barr virus (EBV) monitoring and pre-
vention and donor lymphocyte infusion were performed
according to previous studies [34, 40, 41].
Methodology to detect anti-HLA antibodies
Patient plasma/serum was screened for class I (i.e., HLA-
A,-B,-C) and class II (i.e., HLA-DR) HLA antibodies with
a LABScreen Mixed Kit (One Lambda, Canoga Park, CA,
USA). The samples (7 uL) were incubated with mixed
HLA class I- and class II-coated microspheres for 30 min
in the dark under gentle agitation. The specimens were
then washed before being incubated with anti-human im-
munoglobulin G-conjugated fluorescein isothiocyanate
as described above for the first incubation. Next, the
samples were analyzed with a Luminex 200 flow analyzer
(Luminex, Austin, TX, USA), and the data were analyzed
with the HLA Fusion 3.2 software (One Lambda). The
MFI of anti-HLA antibodies was obtained from the out-
put file generated by the flow analyzer and adjusted for
the background signal using the formula: sample beads −
negative control beads. The samples with a MFI >500
were further tested for the specificity of the antibody,
using a LABScreen Single Antigen Kit (One Lambda).
The MFI was adjusted for the background signal using the
formula described above. The patients and donors under-
went HLA allele typing of at least the A, B, and DRB1 loci
routinely.
Definitions and evaluation
Neutrophil engraftment was defined as achieving an ANC
of 0.5 × 109/L or greater for three consecutive days, and
platelet recovery was defined as achieving a platelet count
of 20 × 109/L or greater, without platelet transfusions, for
seven days. A Hb level of at least 80 g/L without transfu-
sion support is the accepted threshold for red cell engraft-
ment [12]. Full donor chimerism was defined as ≥95 %
leukocytes of donor origin in peripheral blood or marrow
samples, measured according to our previous report. [14]
Mixed chimerism was defined as more than 5 % but less
than 95 % leukocytes of donor origin.
Primary GF included GR and PGF. As described in the
introduction, GR is the failure to engraft neutrophils
(ANC ≤0.5 × 109/L) by day +28 for three consecutive
days and the absence of donor hematopoiesis. Because
delayed red cell engraftment may happen for many months
post-transplant and is more difficult to evaluate in an
unarguable manner, in the present study, primary PGF
was defined as the presence of three cytopenic counts
(ANC ≤0.5 × 109/L, platelet ≤20 × 109/L, or hemoglobin
(Hb) ≤80 g/L) beyond day +28 with a transfusion re-
quirement associated with hypoplastic-aplastic BM, inthe presence of complete donor chimerism. The patients
with evidence of severe GVHD or hematologic relapse
were excluded [14].
The diagnosis and grading of acute and chronic GVHD
was assigned by the transplant center using standard cri-
teria [42, 43]. Transplant-related mortality (TRM), relapse,
DFS, and overall survival (OS) was defined according to
our previous studies [2, 32, 34].
Statistical analysis
The patient baseline characteristics were reported descrip-
tively. The Fisher exact test or Wilcoxon rank sum test
was used for two-group comparisons. Death without
engraftment was considered a competing risk for engraft-
ment, primary GR, and primary PGF, while primary GR
was considered a competing risk for primary PGF. The
surviving patients were censored at their date of last
known follow-up. The log-rank test was used for compari-
sons of Kaplan-Meier curves, and a Gray test was used
for comparisons of cumulative incidence curves. Potential
prognostic factors for OS, DFS, relapse, TRM, and engraft-
ment were examined in proportional hazards models. To
explore whether the DSA intensity, measured as MFI, pre-
dicted primary GF, including GR and PGF, an analysis of
receiver operator characteristics was performed. Cox
regression models were developed to test the impact of
variables on primary GF. Unless otherwise specified, P
values are based on two-sided hypothesis tests. Alpha was
set at 0.05. We used SPSS 16.0 (Mathsoft, Seattle, WA,
USA) for most analyses.
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